FDA Warns Birth Control Pills Yaz, Yasmin and Other Drospirenone Pills: Possible Increase Risk of Blood Clots

FDA Warning – Birth Control Pills Yaz, Yasmin and Other Drospirenone Pills: Possible Increased Risk of Blood Clots
The U.S. Food and Drug Administration (FDA) released a Safety Communication reporting that it “remained concerned” about the potential increased risk of blood clots associated with the use of drospirenone-containing birth control pills. Drospirenone is the synthetic progestin ingredient used in certain birth control pills such as Yaz, Yasmin, Safyal, Beyaz and Zarah (name brands) and Ocella (generic).
The FDA communication followed a review of the preliminary results of a FDA-funded study involving 800,000 women, which revealed a 1.5-fold increase in the risk of blood clots, also known as venous thromboembolism (VTE), for women who use drospirenone-containing birth-control pill, compared to users of other hormonal contraceptives.
Symptoms of blood clots include persistent leg pain, severe chest pain, or sudden shortness of breath.
Full FDA Safety Communication

About The Author

Laura Hack

Laura Hack

Laura Hack is a paralegal with Terrell • Hogan. She has been with the firm since 1996 and has worked primarily for Wayne Hogan. She is an experienced Paralegal with 30+ years of working in the law practice industry. Skilled in Appeals, Civil Trial Litigation Support, Torts, Trial Practice, and Pleadings.